EU MDR PMCF under Article 61 and Annex XIV Part B

1. Key takeaways

Post-market clinical follow-up (PMCF) is a continuous process conducted by the manufacturer under Article 61 of the MDR to proactively collect and evaluate clinical data from devices that have been placed on the market or put into service in the European Union, for the purposes of confirming their safety and performance, verifying the benefit-risk determination, and identifying previously unknown side-effects. The procedures and methods are set out in Part B of Annex XIV.

PMCF is not a one-off study or an optional appendix to the clinical evaluation. It is the mechanism through which real-world evidence about the device keeps flowing back into the clinical evaluation report, the risk management file and the technical documentation, and its findings feed the PSUR under Article 86(1)(b). Devices that skip or thin out PMCF accumulate an evidential debt that becomes visible at the next notified body assessment.

In planning terms, PMCF should be scoped when the clinical evaluation is scoped, not after the device is certified. The residual questions identified in the clinical evaluation report determine which PMCF methods are meaningful, and the PMCF plan in turn determines what the next evaluation update can say. Budgeting for PMCF at project start, instead of discovering the obligation after market placement, is one of the clearest differences between mature and struggling post-market programmes.

2. Legal basis

The PMCF obligations arise from Article 61 of Regulation (EU) 2017/745 together with Annex XIV, and connect to the PMS and PSUR provisions listed below.

3. Expert insights

Insight 1: PMCF is a continuation of the clinical evaluation, not a new project separate from it.

Article 61(11) positions PMCF as a continuous process conducted in accordance with Article 61(1), and its results are an evidence source for the continuous updating of the clinical evaluation. Part B of Annex XIV requires the PMCF plan to contain the methods and procedures to be used, and makes clear that the results of PMCF must be used to update the clinical evaluation report, the risk management documents and the technical documentation. Companies that treat PMCF as a standalone study disconnected from the clinical evaluation file produce data that cannot be reconciled with the conclusions in the CER, which is a recurring finding in technical documentation reviews. A useful test is to ask what the next clinical evaluation update will cite: if the answer is only literature search results and complaint data, the PMCF plan is probably too thin for the device class.

Insight 2: The data collection methods of PMCF each have their own conditions of applicability.

The common methods under Part B of Annex XIV include registries, targeted follow-up studies, structured user surveys and post-market clinical investigations. The selection is usually driven by the risk class of the device, the nature of the residual clinical questions and the quality of the data that can realistically be obtained (a practical estimate). Whatever combination is chosen, the method selection must be justified in the PMCF plan, not decided after the fact. A plan that names methods without explaining why they are adequate for the residual questions will be challenged during assessment.

Insight 3: PMCF and the PSUR stand in an upstream and downstream relationship.

Under Article 86(1)(b), the PSUR must set out the main findings of the PMCF. This creates a closed loop: PMCF produces data, the PSUR summarises them, the clinical evaluation is updated, and risk management and the technical documentation follow. If any segment of this chain breaks, whether because PMCF stops generating data or because the findings never reach the risk management file, the break surfaces during technical documentation review or during surveillance audits. Maintaining the loop is a year-round operating discipline rather than a document exercise. Companies can make the loop visible by dating every hand-off: the PMCF report, the PSUR section, the evaluation update and the risk management review should each reference the stage they were derived from, so that the chain can be reconstructed in minutes during an audit.

Insight 4: Article 61(12) requires PMCF to be embedded in the PMS system.

Under Article 61(12), PMCF becomes a component of clinical evaluation and of the post-market surveillance system. The practical meaning is that the data collection mechanisms of PMCF should share infrastructure with the data collection mechanisms of PMS, avoiding two parallel systems that produce inconsistent data (a practical estimate). Where the two systems are separate, discrepancies between complaint records, registry data and survey data raise questions that are difficult to answer during an audit.

4. Practical recommendations

The measures below aim at integration: PMCF that runs inside the existing PMS infrastructure is cheaper to operate and harder to forget than a separate study track.

1. Build the PMCF plan against Part B of Annex XIV, stating the rationale for method selection, the basis for sample sizes and the schedule.
2. Integrate PMCF data collection and PMS data collection on the same data platform to avoid a dual-track system.
3. Establish a trigger mechanism running from PMCF findings to clinical evaluation update, to risk management update, to technical documentation update.
4. Keep the PMCF section of the PSUR consistent with the PMCF report in both data and conclusions.
5. For devices without PMCF data, state why PMCF is not applicable and provide alternative evidence (a practical estimate).

5. Verification checklist

Use the checklist below before each clinical evaluation update and before notified body surveillance audits.

• □ PMCF plan has been prepared in line with Part B of Annex XIV
• □ Method selection (registry, follow-up study, user survey, post-market clinical investigation) has been justified
• □ PMCF data collection is integrated with the PMS platform
• □ Mechanism returning PMCF findings to clinical evaluation and risk management is in place
• □ PMCF findings in the PSUR are consistent with the PMCF report
• □ Cases where PMCF is not applicable are documented with reasons (where applicable)

Regulatory information verified as of 29 October 2026.

GRZAN regulatory support. GRZAN assists medical device manufacturers with post-market compliance in the European Union market under Regulation (EU) 2017/745, covering PMCF planning and execution, vigilance reporting, field safety corrective action (FSCA) recalls, and responses to competent authority inspections. If you need support with your EU MDR post-market obligations, contact info@grzanglobal.com.